Stryker: Robotic Surgery Momentum Meets the First Real Tariff Test

Stryker Corporation reports first-quarter 2026 earnings tomorrow after market close, with Wall Street watching whether the medical technology leader can sustain the double-digit growth momentum that powered its exceptional 2025 finish. The central question: can Stryker maintain its position at the high end of MedTech growth while navigating incremental cost pressures from tariffs and interest expenses, or will margin headwinds begin to weigh on the earnings trajectory that has consistently beaten estimates for four consecutive quarters?

Part 1: Earnings Preview

Stryker Corporation is a global leader in medical technologies, offering innovative products and services across three segments: MedSurg and Neurotechnology (surgical equipment, endoscopy, medical devices), Neurotechnology (neurovascular and neurosurgical products), and Orthopaedics (joint replacement, trauma, spine). The company impacts more than 150 million patients annually and has established itself as a consistent growth driver in the medical device sector.

Stryker reports Q1 2026 earnings on April 30, 2026, after market close. The consensus estimate stands at $2.98 per share on expected revenue of approximately $6.29 billion. The company most recently reported Q4 2025 earnings of $4.47 per share, beating estimates by $0.07 and delivering 11.4% revenue growth to $7.17 billion. Compared to Q1 2025's reported earnings of $2.84 per share, the current estimate of $2.98 implies +4.93% year-over-year growth—a notable deceleration from the double-digit pace that characterized 2025.

Three key themes define this earnings story:

Procedural Volume Sustainability: After surpassing $25 billion in annual revenue, investors are watching whether healthy hospital procedural volumes can continue supporting organic growth in the 8-9.5% range that management guided for 2026. The momentum exiting 2025 was exceptional, with Q4 organic sales up 11.0%, but the question is whether this pace is sustainable or represented a pull-forward of demand.

Margin Pressure from Tariffs and Costs: Management explicitly flagged "incremental cost pressures from tariffs" and "higher interest expenses" heading into 2026. With adjusted operating margin expanding 100 basis points in both 2024 and 2025, the Street is focused on whether Stryker can maintain margin discipline or if these headwinds will compress profitability despite strong top-line growth.

Mako Robotics and Capital Equipment Momentum: The Mako robotic platform continues driving differentiation in Orthopaedics, with installations and utilization rising in knee and hip procedures. Capital equipment demand—including surgical tools, endoscopy systems, and medical devices—has been robust, supported by an elevated order backlog. However, softer capital spending in parts of Europe could create geographic variability.

Analysts remain constructive heading into the print. The consensus has 18 Strong Buys and 3 Moderate Buys against only 6 Holds, with sentiment improving over the past month. The average price target of $423.92 implies significant upside from current levels, though the stock has pulled back from recent highs. One analyst noted that "having surpassed $25 billion in revenue, we enter 2026 with significant momentum and are poised to continue delivering growth at the high end of MedTech," while another highlighted that "continued product innovation, sales force specialization and tuck-in acquisitions should further bolster performance."

Part 2: Historical Earnings Performance

Stryker has established a consistent pattern of beating earnings estimates, delivering positive surprises in each of the last four quarters. The beats have been modest but reliable: +4.03% in Q1 2025, +2.29% in Q2 2025, +1.59% in Q3 2025, and +1.59% in Q4 2025. This track record demonstrates management's ability to guide conservatively and execute effectively, with the company consistently finding 2-4% upside to Street expectations.

The earnings progression shows strong sequential momentum through 2025. Reported EPS climbed from $2.84 in Q1 to $3.13 in Q2, $3.19 in Q3, and $4.47 in Q4—a pattern reflecting both seasonal strength in Q4 (typically the company's strongest quarter) and sustained operational execution. The Q4 figure represented a particularly strong finish, with the $4.47 result beating the $4.40 estimate despite tougher year-over-year comparisons.

The consistency of these beats—never missing over the past year and maintaining surprise percentages in a tight 1.6-4.0% range—suggests disciplined guidance practices rather than wild volatility. This pattern gives investors confidence that Stryker's Q1 2026 estimate of $2.98 may similarly prove conservative, though the magnitude of any potential beat will be closely watched given the company's commentary about incremental cost pressures heading into 2026.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Stryker reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price behavior shows Day +1 moves averaging 2.29% in absolute terms, with a wide range averaging 3.76%—indicating significant post-earnings volatility. The most recent earnings cycle (January 2026) exemplifies this pattern: after a modest -0.99% Day 0 decline, the stock surged +4.31% on Day +1 following the strong Q4 beat, with an intraday range of 3.51%. This represented the strongest positive reaction in the recent history.

The eight-quarter pattern reveals mixed directional outcomes but consistent volatility. While Day 0 moves average just 0.84% (reflecting pre-announcement positioning), Day +1 reactions have been more pronounced, ranging from a -3.80% decline (July 2025) to the +4.31% surge (January 2026). Notably, five of the last eight earnings releases resulted in Day +1 declines despite the company beating estimates in each case—suggesting the market often prices in beats ahead of time or reacts to guidance and margin commentary rather than the headline EPS number alone.

The 3.76% average Day +1 range indicates investors should prepare for meaningful intraday swings regardless of direction. The stock has demonstrated particular sensitivity to forward guidance and margin outlook, with the largest negative reactions (July and October 2025) occurring despite earnings beats, likely reflecting concerns about sustainability of growth rates or cost pressures.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 5.02% through the May 15 expiration (16 days out), which encompasses this earnings event. This implied move is notably higher than the 2.29% average historical Day +1 move, suggesting options traders are pricing in above-average volatility for this release—possibly reflecting uncertainty around the tariff impact, margin trajectory, or sustainability of the double-digit growth rates that characterized 2025.

Part 3: What Analysts Are Saying

Analyst sentiment on Stryker remains decidedly bullish heading into earnings. The consensus rating stands at 4.44 out of 5.0—firmly in Strong Buy territory—with 18 Strong Buys, 3 Moderate Buys, and 6 Holds. Notably, there are zero Sell or Strong Sell ratings among the 27 analysts covering the stock, reflecting broad confidence in the company's competitive positioning and growth trajectory.

The average price target of $423.92 implies substantial upside of approximately 34.5% from the current price of $315.13, with the range of estimates spanning from a low of $357.00 to a high of $469.00. This wide target range—over $112 between the most bearish and most bullish views—reflects differing opinions on how successfully Stryker can navigate the margin pressures and sustain premium growth rates in 2026.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 17 to 18 while the overall rating ticked up from 4.42 to 4.44. This positive shift suggests analysts are gaining confidence as the earnings date approaches, possibly reflecting constructive channel checks on procedural volumes or capital equipment demand. The improvement comes despite the stock's recent pullback, indicating analysts view current levels as an attractive entry point.

The consensus implies analysts believe Stryker's premium valuation is justified by its position as a high-end MedTech growth story, with the innovation pipeline (particularly Mako robotics), diversified portfolio, and consistent execution supporting continued multiple expansion. However, the 34.5% implied upside also suggests the market is pricing in meaningful skepticism about whether the company can deliver on the bullish scenario—creating a significant gap between where the stock trades and where analysts believe it should trade.

Part 4: Technical Picture

The technical setup heading into earnings is decidedly bearish, with Stryker trading well below all key moving averages and the Barchart Technical Opinion flashing a strong warning signal. The indicator currently reads 100% Sell, unchanged from both one week ago and one month ago, indicating persistent and unrelenting downward pressure with no signs of stabilization.

Timeframe Analysis:

• Short-term (100% Sell): Maximum bearish signal indicates severe near-term weakness with no technical support
• Medium-term (100% Sell): Continued sell signal confirms the intermediate-term trend remains firmly negative
• Long-term (100% Sell): Persistent long-term sell reading suggests structural deterioration in the technical foundation

Trend Characteristics: The signal ranks in the Top 1% with Strongest directional conviction, indicating this is among the most technically impaired stocks in the market—an extremely rare and cautionary setup heading into a catalyst event.

The stock's position relative to moving averages confirms the technical damage. At $315.13, SYK trades below the 5-day MA ($324.55), below the 10-day MA ($329.94), below the 20-day MA ($333.87), below the 50-day MA ($347.75), below the 100-day MA ($353.16), and below the 200-day MA ($365.45). This complete breakdown below all timeframes—with the stock now trading nearly 14% below its 200-day moving average—represents a significant technical deterioration from the momentum that characterized the stock through much of 2025.

The cascading moving average structure, with each shorter-term average below the next longer-term average, defines a classic downtrend with no technical support until much lower levels. The 200-day moving average at $365.45 now represents overhead resistance more than $50 above current levels. This technical setup is particularly challenging heading into earnings: while a strong beat and guidance raise could provide the catalyst needed to reverse the trend, any disappointment or cautious commentary on margins would likely accelerate the existing downward momentum. The 5.02% options-implied move suggests the market is pricing in a significant reaction, and with the stock already in a weakened technical state, the risk/reward skew appears tilted toward further downside if the company fails to deliver a convincing beat-and-raise scenario that addresses tariff and margin concerns.